{ "access": { "embargo": { "active": false, "reason": null }, "files": "public", "record": "public", "status": "open" }, "created": "2020-09-08T17:15:02.380872+00:00", "custom_fields": {}, "deletion_status": { "is_deleted": false, "status": "P" }, "files": { "count": 1, "enabled": true, "entries": { "Respuesta_JFGaston_Nota_AEV_vacuna_gripe_COVID.pdf": { "checksum": "md5:6b19eacabebf4af2218b7ed8b404df37", "ext": "pdf", "id": "4119de45-ca2e-40d2-a183-1bf44d1bc1e4", "key": "Respuesta_JFGaston_Nota_AEV_vacuna_gripe_COVID.pdf", "metadata": null, "mimetype": "application/pdf", "size": 94805 } }, "order": [], "total_bytes": 94805 }, "id": "4019458", "is_draft": false, "is_published": true, "links": { "access": "https://zenodo.org/api/records/4019458/access", "access_links": "https://zenodo.org/api/records/4019458/access/links", "access_request": "https://zenodo.org/api/records/4019458/access/request", "access_users": "https://zenodo.org/api/records/4019458/access/users", "archive": "https://zenodo.org/api/records/4019458/files-archive", "archive_media": "https://zenodo.org/api/records/4019458/media-files-archive", "communities": "https://zenodo.org/api/records/4019458/communities", "communities-suggestions": "https://zenodo.org/api/records/4019458/communities-suggestions", "doi": "https://doi.org/10.5281/zenodo.4019458", "draft": "https://zenodo.org/api/records/4019458/draft", "files": "https://zenodo.org/api/records/4019458/files", "latest": "https://zenodo.org/api/records/4019458/versions/latest", "latest_html": "https://zenodo.org/records/4019458/latest", "media_files": "https://zenodo.org/api/records/4019458/media-files", "parent": "https://zenodo.org/api/records/4019457", "parent_doi": "https://zenodo.org/doi/10.5281/zenodo.4019457", "parent_html": "https://zenodo.org/records/4019457", "requests": "https://zenodo.org/api/records/4019458/requests", "reserve_doi": "https://zenodo.org/api/records/4019458/draft/pids/doi", "self": "https://zenodo.org/api/records/4019458", "self_doi": "https://zenodo.org/doi/10.5281/zenodo.4019458", "self_html": "https://zenodo.org/records/4019458", "self_iiif_manifest": "https://zenodo.org/api/iiif/record:4019458/manifest", "self_iiif_sequence": "https://zenodo.org/api/iiif/record:4019458/sequence/default", "versions": "https://zenodo.org/api/records/4019458/versions" }, "media_files": { "count": 0, "enabled": false, "entries": {}, "order": [], "total_bytes": 0 }, "metadata": { "creators": [ { "person_or_org": { "family_name": "Juan F. Gast\u00f3n A\u00f1a\u00f1os", "name": "Juan F. Gast\u00f3n A\u00f1a\u00f1os", "type": "personal" } } ], "description": "
El 1/07/2020 la Asociación Española de Vacunología emitió la nota (1): “La AEV desmiente categóricamente la información sobre la asociación entre el Polisorbato 80 y la infección por SARS-CoV-2” para intentar rebatir nuestro trabajo (2): “Posible causa de la pandemia por coronavirus: Interferencia inmunológica entre el Polisorbato 80 de la vacuna antigripal adyuvada y el SARS-CoV-2”.
\n\nEn esa nota se argumenta que hay comunidades autónomas en las que no se ha vacunado con la vacuna adyuvada de la gripe. Y en eso llevan razón, pero nuestro trabajo se centra en la vacuna antigripal adyuvada, la que se les había administrado al 91% de los fallecidos, pese a que varios de ellos también habían recibido la del neumococo.
\n\nPues bien, en las comunidades autónomas citadas por la Asociación Española de Vacunología: Navarra, Castilla-La Mancha y La Rioja, no se usó la antigripal adyuvada, pero sí que se administró la vacuna antineumocócica PREVENAR-13, que también contiene Polisorbato 80 (3), al estar incluída en sus protocolos de vacunación para mayores de 65 años, como lo corroboran distintos documentos: Navarra (4), Castilla-La Mancha (5), La Rioja, Madrid, Castilla-León, Galicia, Asturias y Melilla (6).
\n\nParece que la Asociación Española de Vacunología no ha tenido en cuenta que nuestro trabajo se centra no en la propia vacuna sino en el Polisorbato 80, citándose claramente el mecanismo propuesto:
\n\n"Se propone un hipotético mecanismo consistente en una posible interferencia inmunológica, que requiere de la concurrencia de 3 elementos:
\n\nExposición previa relativamente reciente del sujeto a la administración de POLISORBATO 80 por vía parenteral, ya sea a través de la vacuna antigripal adyuvada o de otros fármacos parenterales que lo contengan."...
\n\nEs decir, que se incluye en la sospecha el PREVENAR-13 de esas comunidades.
", "languages": [ { "id": "spa", "title": { "en": "Spanish" } } ], "publication_date": "2020-07-04", "publisher": "Zenodo", "resource_type": { "id": "publication-article", "title": { "de": "Zeitschriftenartikel", "en": "Journal article" } }, "rights": [ { "description": { "en": "The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited." }, "icon": "cc-by-icon", "id": "cc-by-4.0", "props": { "scheme": "spdx", "url": "https://creativecommons.org/licenses/by/4.0/legalcode" }, "title": { "en": "Creative Commons Attribution 4.0 International" } } ], "subjects": [ { "subject": "interferencia inmunol\u00f3gica" }, { "subject": "vacuna gripe adyuvada" }, { "subject": "polisorbatos" }, { "subject": "Polisorbato 80" }, { "subject": "SARS-CoV-2" }, { "subject": "COVID-19" }, { "subject": "tormenta de citoquinas" }, { "subject": "vacuna antineumoc\u00f3cica" }, { "subject": "AEV" }, { "subject": "Asociaci\u00f3n Espa\u00f1ola de Vacunolog\u00eda" } ], "title": "Respuesta a la nota de la AEV de 1 de julio de 2020 en la que desmiente categ\u00f3ricamente la informaci\u00f3n sobre la asociaci\u00f3n entre el Polisorbato 80 y la infecci\u00f3n por SARS-CoV-2", "version": "1" }, "parent": { "access": { "owned_by": { "user": 120434 } }, "communities": { "default": "10f33f78-3f29-41b6-bb10-f757a8f03cb8", "entries": [ { "access": { "member_policy": "open", "members_visibility": "public", "record_policy": "open", "review_policy": "open", "visibility": "public" }, "children": { "allow": false }, "created": "2020-03-16T11:40:44.487619+00:00", "custom_fields": {}, "deletion_status": { "is_deleted": false, "status": "P" }, "id": "10f33f78-3f29-41b6-bb10-f757a8f03cb8", "links": {}, "metadata": { "curation_policy": "The Coronavirus Disease Research Community - COVID-19 is curated by a selected team of experts nominated by OpenAIRE* (see list below). Each time a Zenodo user wants to add a record into the community, an email is sent to the curators that will decide whether to include the record or not.
\r\n\r\nOnly records that may be relevant to the Corona Virus Disease (COVID-19) or the SARS-CoV-2 should be included in this community. The Community curators are not able to edit records, therefore they may ask the corresponding authors to modify the record metadata when necessary, to provide the readers/users with more detailed information according to the FAIR principle of Open Science.
\r\n\r\nIf after its acceptance, a record is subsequently found not to be compliant, we reserve the right to remove it from the community.
\r\n\r\nThe curation team is reachable through the following email address for further clarification or information: covid19@openaire.eu.
\r\n\r\nCurator List:
\r\n\r\n* OpenAIRE: open access and open science training and support since 2009. OpenAIRE is the largest aggregator of European Commission funded research outputs and beyond, also delivering on-demand services for research communities.
\r\n", "page": "This community collects research outputs that may be relevant to the Coronavirus Disease (COVID-19) or the SARS-CoV-2. Scientists are encouraged to upload their outcome in this collection to facilitate sharing and discovery of information. Although Open Access articles and datasets are recommended, also closed and restricted access material are accepted. All types of research outputs can be included in this Community (Publication, Poster, Presentation, Dataset, Image, Video/Audio, Software, Lesson, Other).
\r\n\r\nThe recent Corona Virus Disease (COVID-19) outbreak is requiring unseen efforts of collaboration of the scientific community that need to act fast and to share results in an unpredictable manner. In order to facilitate the Scientist efforts, this community was created to collect all research results that could be relevant for the scientific community working on the Corona Virus Disease (COVID-19) and SARS-CoV-2.
\r\n\r\nAlthough Open Access articles and datasets are recommended, also closed and restricted access material are accepted. All types of research outputs can be included in this Community (Publication, Poster, Presentation, Dataset, Image, Video/Audio, Software, Lesson, Other).
\r\n\r\nWhen depositing a resource that is linked to other resources (not limited to the records deposited in Zenodo but also in other repositories), please make sure that your record is linked to all the other related elements already available, in order to adhere to the FAIR principles of Open Science to maximise the reusability of research results.
\r\n\r\n", "title": "Coronavirus Disease Research Community - COVID-19" }, "revision_id": 0, "slug": "covid-19", "updated": "2021-02-23T14:39:53.029415+00:00" } ], "ids": [ "10f33f78-3f29-41b6-bb10-f757a8f03cb8" ] }, "id": "4019457", "pids": { "doi": { "client": "datacite", "identifier": "10.5281/zenodo.4019457", "provider": "datacite" } } }, "pids": { "doi": { "client": "datacite", "identifier": "10.5281/zenodo.4019458", "provider": "datacite" }, "oai": { "identifier": "oai:zenodo.org:4019458", "provider": "oai" } }, "revision_id": 4, "stats": { "all_versions": { "data_volume": 13462310.0, "downloads": 142, "unique_downloads": 135, "unique_views": 1054, "views": 1100 }, "this_version": { "data_volume": 13462310.0, "downloads": 142, "unique_downloads": 135, "unique_views": 1052, "views": 1098 } }, "status": "published", "updated": "2020-09-13T16:32:02.634984+00:00", "versions": { "index": 1, "is_latest": true } }